药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
Conatumumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Conatumumab.
Tiludronic acid
Human Varicella-Zoster Immune Globulin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Human Varicella-Zoster Immune Globulin.
Tiludronic acid
Eftrenonacog alfa
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Eftrenonacog alfa.
Tiludronic acid
Tetanus Immune Globulin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tetanus Immune Globulin.
Tiludronic acid
Atezolizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Atezolizumab.
Tiludronic acid
Ravulizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ravulizumab.
Tiludronic acid
Ixekizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ixekizumab.
Tiludronic acid
Necitumumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Necitumumab.
Tiludronic acid
Daratumumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Daratumumab.
Tiludronic acid
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Antilymphocyte immunoglobulin (horse).
Tiludronic acid
Evolocumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Evolocumab.
Tiludronic acid
Alirocumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Alirocumab.
Tiludronic acid
Idarucizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Idarucizumab.
Tiludronic acid
Asfotase alfa
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Asfotase alfa.
Tiludronic acid
Dinutuximab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Dinutuximab.
Tiludronic acid
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Anthrax immune globulin human.
Tiludronic acid
Blinatumomab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Blinatumomab.
Tiludronic acid
Dulaglutide
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Dulaglutide.
Tiludronic acid
Pembrolizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Pembrolizumab.
Tiludronic acid
Siltuximab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Siltuximab.